Predicting Drug Treatment Outcomes in Children with Tuberous Sclerosis Complex–Related Epilepsy: A Clinical Radiomics Study

References

1. 1.↵
   1. Randle SC

   . Tuberous sclerosis complex: a review. Pediatr Ann 2017;46:e166– 71 doi:10.3928/19382359-20170320-01 pmid:28414398

   CrossRefPubMed
2. 2.↵
   1. Henske EP,
   2. Jóźwiak S,
   3. Kingswood JC, et al

   . Tuberous sclerosis complex. Nat Rev Dis Primers 2016;2:16035 doi:10.1038/nrdp.2016.35 pmid:27226234

   CrossRefPubMed
3. 3.↵
   1. Curatolo P,
   2. Nabbout R,
   3. Lagae L, et al

   . Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol 2018;22:738–48 doi:10.1016/j.ejpn.2018.05.006 pmid:29880258

   CrossRefPubMed
4. 4.↵
   1. Słowińska M,
   2. Jóźwiak S,
   3. Peron A, et al

   . Early diagnosis of tuberous sclerosis complex: a race against time: how to make the diagnosis before seizures? Orphanet J Rare Dis 2018;13:25 doi:10.1186/s13023-018-0764-z pmid:29378663

   CrossRefPubMed
5. 5.↵
   1. Fohlen M,
   2. Taussig D,
   3. Ferrand-Sorbets S, et al

   . Refractory epilepsy in preschool children with tuberous sclerosis complex: early surgical treatment and outcome. Seizure 2018;60:71–79 doi:10.1016/j.seizure.2018.06.005 pmid:29929109

   CrossRefPubMed
6. 6.↵
   1. Gül Mert G,
   2. Altunbaşak Ş,
   3. Hergüner Ö, et al

   . Factors affecting epilepsy prognosis in patients with tuberous sclerosis. Childs Nerv Syst 2019;35:463–68 doi:10.1007/s00381-019-04066-7 pmid:30673834

   CrossRefPubMed
7. 7.↵
   1. van der Poest Clement E,
   2. Jansen FE,
   3. Braun KP, et al

   . Update on drug management of refractory epilepsy in tuberous sclerosis complex. Paediatr Drugs 2020;22:73–84 doi:10.1007/s40272-019-00376-0 pmid:31912454

   CrossRefPubMed
8. 8.↵
   1. Jóźwiak S,
   2. Kotulska K,
   3. Domańska-Pakieła D, et al

   . Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 2011;15:424–31 doi:10.1016/j.ejpn.2011.03.010 pmid:21507691

   CrossRefPubMed
9. 9.↵
   1. Jesmanas S,
   2. Norvainytė K,
   3. Gleiznienė R, et al

   . Different MRI-defined tuber types in tuberous sclerosis complex: quantitative evaluation and association with disease manifestations. Brain Dev 2018;40:196–204 doi:10.1016/j.braindev.2017.11.010 pmid:29258718

   CrossRefPubMed
10. 10.↵
    1. Yang J,
    2. Zhao C,
    3. Su S, et al

    . Machine learning in epilepsy drug treatment outcome prediction using multi-modality data in children with tuberous sclerosis complex. In: Proceedings of the 2020 6th International Conference on Big Data and Information Analytics (BigDIA), Shenzhen, China; December 4–6, 2020
11. 11.↵
    1. Russo C,
    2. Nastro A,
    3. Cicala D, et al

    . Neuroimaging in tuberous sclerosis complex. Childs Nerv Syst 2020;36:2497–509 doi:10.1007/s00381-020-04705-4 pmid:32519125

    CrossRefPubMed
12. 12.↵
    1. Grilli G,
    2. Moffa AP,
    3. Perfetto F, et al

    . Neuroimaging features of tuberous sclerosis complex and Chiari type I malformation: a rare association. J Pediatr Neurosci 2018;13:224–28 doi:10.4103/jpn.JPN_76_17 pmid:30090143

    CrossRefPubMed
13. 13.↵
    1. Hulshof HM,
    2. Benova B,
    3. Krsek P, et al

    . The epileptogenic zone in children with tuberous sclerosis complex is characterized by prominent features of focal cortical dysplasia. Epilepsia Open 2021;6:663–71 doi:10.1002/epi4.12529 pmid:34328682

    CrossRefPubMed
14. 14.↵
    1. Stafstrom CE,
    2. Staedtke V,
    3. Comi AM

    . Epilepsy mechanisms in neurocutaneous disorders: tuberous sclerosis complex, neurofibromatosis type 1, and Sturge-Weber syndrome. Front Neurol 2017;8:87 doi:10.3389/fneur.2017.00087 pmid:28367137

    CrossRefPubMed
15. 15.↵
    1. Mayerhoefer ME,
    2. Materka A,
    3. Langs G, et al

    . Introduction to radiomics. J Nucl Med 2020;61:488–95 doi:10.2967/jnumed.118.222893 pmid:32060219

    Abstract/FREE Full Text
16. 16.↵
    1. Yip SS,
    2. Aerts HJ

    . Applications and limitations of radiomics. Phys Med Biol 2016;61:R150–66 doi:10.1088/0031-9155/61/13/R150 pmid:27269645

    CrossRefPubMed
17. 17.↵
    1. Rizzo S,
    2. Botta F,
    3. Raimondi S, et al

    . Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp 2018;2:36 doi:10.1186/s41747-018-0068-z pmid:30426318

    CrossRefPubMed
18. 18.↵
    1. Liu Z,
    2. Wang Y,
    3. Liu X, et al

    . Radiomics analysis allows for precise prediction of epilepsy in patients with low-grade gliomas. Neuroimage Clin 2018;19:271–78 doi:10.1016/j.nicl.2018.04.024 pmid:30035021

    CrossRefPubMed
19. 19.↵
    1. Park YW,
    2. Choi YS,
    3. Kim SE, et al

    . Radiomics features of hippocampal regions in magnetic resonance imaging can differentiate medial temporal lobe epilepsy patients from healthy controls. Sci Rep 2020;10:19567 doi:10.1038/s41598-020-76283-z pmid:33177624

    CrossRefPubMed
20. 20.↵
    1. Sun K,
    2. Liu Z,
    3. Li Y, et al

    . Radiomics analysis of postoperative epilepsy seizures in low-grade gliomas using preoperative MR images. Front Oncol 2020;10:1096 doi:10.3389/fonc.2020.01096 pmid:32733804

    CrossRefPubMed
21. 21.↵
    1. Wang Y,
    2. Wei W,
    3. Liu Z, et al

    . Predicting the type of tumor-related epilepsy in patients with low-grade gliomas: a radiomics study. Front Oncol 2020;10:235 doi:10.3389/fonc.2020.00235 pmid:32231995

    CrossRefPubMed
22. 22.↵
    1. Zhang Y,
    2. Yan P,
    3. Liang F, et al

    . Predictors of epilepsy presentation in unruptured brain arteriovenous malformations: a quantitative evaluation of location and radiomics features on T2-weighted imaging. World Neurosurg 2019;125:e1008–15 doi:10.1016/j.wneu.2019.01.229 pmid:30771548

    CrossRefPubMed
23. 23.↵
    1. He B,
    2. Dong D,
    3. She Y, et al

    . Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. J Immunother Cancer 2020;8:e000550 doi:10.1136/jitc-2020-000550 pmid:32636239

    CrossRefPubMed
24. 24.↵
    1. Khorrami M,
    2. Prasanna P,
    3. Gupta A, et al

    . Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer. Cancer Immunol Res 2020;8:108–19 doi:10.1158/2326-6066.CIR-19-0476 pmid:31719058

    Abstract/FREE Full Text
25. 25.↵
    1. Sun R,
    2. Limkin EJ,
    3. Vakalopoulou M, et al

    . A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018;19:1180–91 doi:10.1016/S1470-2045(18)30413-3 pmid:30120041

    CrossRefPubMed
26. 26.↵
    1. Trebeschi S,
    2. Drago SG,
    3. Birkbak NJ, et al

    . Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol 2019;30:998–1004 doi:10.1093/annonc/mdz108 pmid:30895304

    CrossRefPubMed
27. 27.↵
    1. Tunali I,
    2. Gray JE,
    3. Qi J, et al

    . Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: an early report. Lung Cancer 2019;129:75–79 doi:10.1016/j.lungcan.2019.01.010 pmid:30797495

    CrossRefPubMed
28. 28.↵
    1. Isensee F,
    2. Schell M,
    3. Pflueger I, et al

    . Automated brain extraction of multisequence MRI using artificial neural networks. Hum Brain Mapp 2019;40:4952–64 doi:10.1002/hbm.24750 pmid:31403237

    CrossRefPubMed
29. 29.↵
    1. van Griethuysen JJ,
    2. Fedorov A,
    3. Parmar C, et al

    . Computational radiomics system to decode the radiographic phenotype. Cancer Res 2017;77:e104–07 doi:10.1158/0008-5472.CAN-17-0339 pmid:29092951

    Abstract/FREE Full Text
30. 30.↵
    1. Austin PC,
    2. Harrell FE Jr.,
    3. van Klaveren D

    . Graphical calibration curves and the integrated calibration index (ICI) for survival models. Stat Med 2020;39:2714–42 doi:10.1002/sim.8570 pmid:32548928

    CrossRefPubMed
31. 31.↵
    1. Hsieh DT,
    2. Jennesson MM,
    3. Thiele EA

    . Epileptic spasms in tuberous sclerosis complex. Epilepsy Res 2013;106:200–10 doi:10.1016/j.eplepsyres.2013.05.003 pmid:23796861

    CrossRefPubMed
32. 32.↵
    1. Liu S,
    2. Yu T,
    3. Guan Y, et al

    . Resective epilepsy surgery in tuberous sclerosis complex: a nationwide multicentre retrospective study from China. Brain 2020;143:570–81 doi:10.1093/brain/awz411 pmid:31953931

    CrossRefPubMed
33. 33.↵
    1. Zhang G,
    2. Xu L,
    3. Zhao L, et al

    . CT-based radiomics to predict the pathological grade of bladder cancer. Eur Radiol 2020;30:6749–56 doi:10.1007/s00330-020-06893-8 pmid:32601949

    CrossRefPubMed
34. 34.↵
    1. Mao B,
    2. Zhang L,
    3. Ning P, et al

    . Preoperative prediction for pathological grade of hepatocellular carcinoma via machine learning-based radiomics. Eur Radiol 2020;30:6924–32 doi:10.1007/s00330-020-07056-5 pmid:32696256

    CrossRefPubMed
35. 35.↵
    1. Jiang Y,
    2. Chen C,
    3. Xie J, et al

    . Radiomics signature of computed tomography imaging for prediction of survival and chemotherapeutic benefits in gastric cancer. EBioMedicine 2018;36:171–82 doi:10.1016/j.ebiom.2018.09.007 pmid:30224313

    CrossRefPubMed
36. 36.↵
    1. Staal FC,
    2. van der Reijd DJ,
    3. Taghavi M, et al

    . Radiomics for the prediction of treatment outcome and survival in patients with colorectal cancer: a systematic review. Clin Colorectal Cancer 2021;20:52–71 doi:10.1016/j.clcc.2020.11.001 pmid:33349519

    CrossRefPubMed
37. 37.↵
    1. Lambin P,
    2. Leijenaar RT,
    3. Deist TM, et al

    . Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017;14:749–62 doi:10.1038/nrclinonc.2017.141 pmid:28975929

    CrossRefPubMed
38. 38.↵
    1. Zhao X,
    2. Jiang D,
    3. Hu Z, et al

    . Machine learning and statistic analysis to predict drug treatment outcome in pediatric epilepsy patients with tuberous sclerosis complex. Epilepsy Res 2022;188:107040 doi:10.1016/j.eplepsyres.2022.107040 pmid:36332542

    CrossRefPubMed
39. 39.↵
    1. Jeong A,
    2. Nakagawa JA,
    3. Wong M

    . Predictors of drug-resistant epilepsy in tuberous sclerosis complex. J Child Neurol 2017;32:1092–98 doi:10.1177/0883073817737446 pmid:29129154

    CrossRefPubMed
40. 40.↵
    1. Chu-Shore CJ,
    2. Major P,
    3. Camposano S, et al

    . The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010;51:1236–41 doi:10.1111/j.1528-1167.2009.02474.x pmid:20041940

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Salussolia CL,
    2. Klonowska K,
    3. Kwiatkowski DJ, et al

    . Genetic etiologies, diagnosis, and treatment of tuberous sclerosis complex. Annu Rev Genomics Hum Genet 2019;20:217–40 doi:10.1146/annurev-genom-083118-015354 pmid:31018109

    CrossRefPubMed